The peer-reviewed version of our manuscript describing the influence of the #SARSCoV2 spike glycoprotein conformation on vaccine- and infection-elicited antibody responses in humans is out!
During the review process, we expanded our panel of vaccinee plasma samples to also include subjects that received 2 doses of Jansen Ad26.COV2.S. or of Novavax NVX-CoV2373, thereby covering all 4 vaccines authorized or approved in the US (and several others used worldwide)
3/
We show that vaccines containing prefusion-stabilizing S mutations (S-2P) elicit antibody responses in humans with enhanced recognition of S and the S1 subunit relative to postfusion S, as compared to vaccines lacking these mutations or natural infection.
4/
We also found that vaccination of individuals previously infected (WA-1, 2020), with one of 3 vaccines tested, also preferentially boosted prefusion S as well as S1 antibody binding titers!
5/
We extended the correlation between plasma neutralizing activity and the magnitude of antibody responses to the S1 subunit (in addition to S, prefusion S2, RBD, NTD but not postfusion S2) for all vaccines evaluated and for infection-elicited polyclonal antibodies
6/
We show that depletion of prefusion S or S1 subunit-targeting antibodies resulted in a near-complete loss of neutralizing activity whereas depletion using prefusion or postfusion S2 had no detectable impact.
7/
It is therefore S1 subunit shedding rather than S2 conformational changes associated with the prefusion to postfusion transition that leads to a marked loss of potency due to the fact that most neutralizing antibodies target the RBD and the NTD.
8/
This highlights one of the grand challenges we (as a field) have to overcome to elicit broadly neutralizing antibodies against betacoronaviruses or even all coronaviruses!
9/
Towards this goal and as part of this work, we designed and determined a #CryoEM structure of a prefusion S2 trimer (prefusion tertiary structure with more open quaternary structure than prefusion S) described in the supplemental material!
The peer-reviewed version of our manuscript assessing human neutralizing antibodies against key #Omicron variant sublineages elicited by a comprehensive panel of vaccines is now out
The thread describing our @biorxivpreprint submission can be found here and we added a large amount of data during the reviewing process (cf. thread below).
To understand how the constellations of spike mutations present in each #SARSCoV2#Omicron variant impact entry into cells, we compared the functional properties of the Wuhan-Hu-1/G614, Delta, BA.1, BA.2, BA.2.12.1, and BA.4/5 variants.
During the reviewing process, we determined a crystal structure of the CCoV-HuPn-2018 RBD/B domain bound to canine APN revealing that receptor recognition involves similar interactions to PRCV RBD bound to porcine APN.
With stunning & key contacts with the APN N747 glycan!
We assessed plasma neutralizing activity from humans previously infected in 2020 (WA-1-like) and then vaxed 2x or 3x, or vaxed before Delta or #Omicron BA.1 breakthrough infection or vaxed-'only' 3x
2/24
#Omicron breakthrough cases had highest neutralizing activity against #SARSCoV2 variants, possibly due to exposure to BA.1 spike whereas neutralization of SARS-CoV-1 was low for all cohorts, due to genetic and antigenic divergence of the latter spike
Excited to share our latest serological data evaluating plasma neutralizing antibody responses and immune evasion associated with the constellation of spike mutations present in the #Omicron BA.1 and BA.2 variants.
We compared side-by-side the plasma neutralizing activity elicited in humans by seven #COVID19 vaccines (Moderna, Pfizer, Novavax, Janssen, AstraZeneca, Sputnik V and Sinopharm) or SARS-CoV-2 Washington-1 infection. We cover mRNA, Ad-vectored and protein subunit vaccines!
2/13
We found that the large number of BA.1 and BA.2 spike mutations severely dampen plasma neutralizing activity elicited by infection or primary vaccine series, with a more marked effect for BA.1 compared to BA.2 across all groups.
Throughout the pandemic, we have been puzzled with inconsistencies in the observed breadth of polyclonal serum neutralizing antibodies against #SARSCoV2 variants in mice vs humans or non-human primates.
Serum neutralizing antibodies titers represent the current best correlate of protection against #SARSCoV2 used to evaluate and compare vaccine-elicited immunity in animal models and humans.
Vaccine-elicited serum neutralizing activity was less sensitive to #SARSCoV2 variants (less affected) in mice than in non-human primates or humans, regardless of overall titer, vaccine platform (protein subunit vs mRNA), mouse strain, cell type, or antigen (RBD vs spike)...
Delighted to share our study of the #SARSCoV2 E406W spike mutant describing how a single amino acid mutation mediates escape from the REGN10987/REGN10933 antibody cocktail despite residing outside their epitopes
We determined a #CryoEM structure of the E406W spike trimer and observed a remodeling of the receptor-binding domain (RBD), hindering binding of clinical antibodies such as the REGN10987/REGN10933 cocktail or COV2-2130